Who is sponsoring NCT06407232?

NCT06407232 is sponsored by University of Wisconsin, Madison.

What condition does NCT06407232 study?

NCT06407232 studies Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant.

What is the status of NCT06407232?

NCT06407232 is currently RECRUITING.

Last reviewed 2025-10-06 · How we verify

An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients

NCT06407232 Phase 3 RECRUITING

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Details

Lead sponsor	University of Wisconsin, Madison
Phase	Phase 3
Status	RECRUITING
Enrolment	90
Start date	2024-08-08
Completion	2026-09

Conditions

Cytomegalovirus Infections
Kidney Transplant Infection
Pancreas Transplant

Interventions

Letermovir

Primary outcomes

Number of distinct episodes of any cytomegalovirus replication greater than 1000 IU/mL — up to 90 days after withdrawal of secondary prophylaxis (up to 6 months on study)
To test the hypothesis that letermovir will be associated with reduced incidence of recurrent viremia, recurrence will be measured defined as incidence of any cytomegalovirus replication greater than 1000 IU/mL requiring treatment after withdrawal of secondary prophylaxis.
Duration of valganciclovir (VGC) Treatment — up to 2 months
To test the hypothesis that letermovir will be associated with reduced duration of (val)ganciclovir treatment, the duration of VGC treatment will be measured.

Countries

United States